According to Gram Research analysis, patients with low vitamin D levels experienced significantly more side effects from PD-1/PD-L1 cancer immunotherapy: 62.5% of those with deficient vitamin D had immune-related side effects compared to just 8.3% with sufficient vitamin D. A 2026 retrospective study of 35 cancer patients found vitamin D levels showed a clear stepwise association with side effect risk (P=0.008). However, researchers emphasize this is early hypothesis-generating evidence and cannot yet prove low vitamin D causes these problems or predict individual risk.

Researchers studied whether vitamin D levels affect side effects from a popular cancer treatment called PD-1/PD-L1 inhibitors. They looked at 35 patients with lung cancer who received this immunotherapy and checked their vitamin D levels. Patients with low vitamin D were much more likely to experience immune-related side effects compared to those with healthy vitamin D levels. The findings suggest vitamin D may play a role in how the body reacts to this type of cancer treatment, though more research is needed to understand if low vitamin D actually causes these problems or just happens alongside them.

Key Statistics

A 2026 retrospective study of 35 cancer patients found that 62.5% of those with deficient vitamin D experienced immune-related side effects from PD-1/PD-L1 inhibitors, compared to just 8.3% of those with sufficient vitamin D levels.

According to research reviewed by Gram, patients with immune-related side effects from immunotherapy had significantly lower median vitamin D levels (26.70 nmol/L) compared to those without side effects (45.50 nmol/L), with a P-value of 0.007.

In a 2026 analysis of 46 vitamin D measurements from 35 immunotherapy patients, side effect rates decreased stepwise across vitamin D categories: 60.0% in deficient patients, 20.0% in insufficient patients, and 6.3% in sufficient patients (Cochran-Armitage trend P=0.003).

The Quick Take

  • What they studied: Whether patients with low vitamin D levels experience more side effects when taking PD-1/PD-L1 inhibitor drugs, which are used to treat certain cancers by boosting the immune system.
  • Who participated: 35 patients with lung cancer who received PD-1/PD-L1 inhibitor therapy between October 2023 and April 2026 at a single medical center. The study looked at 46 vitamin D measurements from these patients.
  • Key finding: Patients with low vitamin D had significantly more immune-related side effects: 62.5% of those with deficient vitamin D experienced side effects, compared to just 8.3% of those with sufficient vitamin D levels. The trend was statistically significant (P=0.008).
  • What it means for you: If you’re receiving immunotherapy for cancer, your doctor may want to check your vitamin D levels. Low vitamin D appears connected to more side effects, though it’s unclear whether raising vitamin D would prevent these problems. This is early research and shouldn’t change your treatment without talking to your oncologist.

The Research Details

This was a retrospective study, meaning researchers looked back at medical records from patients who had already received treatment. They examined vitamin D blood test results from 35 cancer patients treated with PD-1/PD-L1 inhibitors and compared these levels to side effects the patients experienced. The researchers classified vitamin D levels into three categories: deficient (very low), insufficient (moderately low), and sufficient (healthy). They then looked for patterns between vitamin D levels and immune-related side effects, which are unwanted reactions caused by the immune system becoming overactive during this type of cancer treatment.

The main analysis used each patient’s first vitamin D measurement to avoid counting the same person multiple times. The researchers also did a separate analysis looking at all 46 individual measurements to see if patterns held up. They graded side effects using a standard medical scale called CTCAE version 5.0, which helps doctors describe how serious side effects are.

This type of study is useful for spotting patterns and generating new ideas for research, but it has limitations because it relies on existing medical records rather than carefully planned measurements.

Understanding what factors influence side effects from immunotherapy is important because these side effects can be serious and sometimes require stopping treatment. If vitamin D levels truly affect side effect risk, doctors could potentially screen patients before treatment and consider vitamin D supplementation as a way to reduce problems. This research approach allows scientists to quickly examine real-world patient data to form hypotheses that can be tested in larger, more controlled studies.

This study is small (only 35 patients) and looks back at existing medical records, which makes it exploratory rather than definitive. The researchers note that in 10 of 11 cases, the side effect happened before the vitamin D was measured, creating uncertainty about which came first. The study was conducted at a single medical center, so results may not apply to all patients everywhere. The authors themselves emphasize these findings are hypothesis-generating and cannot prove that low vitamin D causes side effects. Larger prospective studies with planned vitamin D measurements before treatment begins would provide stronger evidence.

What the Results Show

In the main patient-level analysis using each person’s first vitamin D test, the researchers found a clear stepwise pattern: patients with deficient vitamin D had the highest rate of immune-related side effects at 62.5%, those with insufficient vitamin D had 13.3%, and those with sufficient vitamin D had only 8.3%. This downward trend was statistically significant (P=0.008), meaning it’s unlikely to have happened by chance alone.

When researchers looked at the actual vitamin D numbers, patients who experienced side effects had lower average vitamin D levels (median of 26.70 nmol/L) compared to those without side effects (median of 45.50 nmol/L). This difference was statistically significant (P=0.007). However, when they simply compared low vitamin D (deficient or insufficient combined) versus sufficient vitamin D, the difference wasn’t quite statistically significant, though patients with low vitamin D still had higher odds of side effects (odds ratio of 4.813).

The exploratory analysis looking at all 46 individual measurements showed similar patterns, with side effect rates of 60.0% in the deficient group, 20.0% in the insufficient group, and 6.3% in the sufficient group (P=0.003). This consistency across both analyses suggests the pattern is real rather than random.

The study documented 11 immune-related side effects total in 9 patients. After excluding one event that couldn’t be verified as immune-related (isolated low potassium), 8 patients had confirmed side effects in the primary analysis. The side effects included various conditions triggered by the immune system overreacting during immunotherapy. The researchers noted that in most cases (10 of 11), the side effect was documented before the vitamin D measurement was taken, which creates uncertainty about timing and causality.

This research adds to growing evidence that vitamin D plays a role in immune function and may influence how the body responds to immunotherapy. Previous studies have shown vitamin D affects immune system regulation, but its specific connection to side effects from PD-1/PD-L1 inhibitors hasn’t been well studied. The findings align with the known immunomodulatory effects of vitamin D, meaning vitamin D appears to influence how the immune system works. However, this is one of the first studies specifically examining this relationship in cancer patients receiving this type of treatment.

The study is small with only 35 patients, which limits how much we can trust the findings. It’s a retrospective study using existing medical records rather than a prospective study with planned measurements, which can introduce errors and missing information. The timing problem is significant: in most cases, the side effect happened before the vitamin D was measured, making it impossible to know if low vitamin D caused the problem or if the immune reaction caused both the side effect and changes in vitamin D. The study was done at one medical center, so results may not apply to different patient populations or treatment settings. The researchers couldn’t account for other factors that might influence both vitamin D levels and side effects, such as diet, sun exposure, supplements, or other health conditions. The authors emphasize these limitations mean the findings cannot establish cause and effect or predict who will have side effects.

The Bottom Line

If you’re receiving PD-1/PD-L1 inhibitor therapy for cancer, ask your doctor about checking your vitamin D levels as part of routine monitoring. This is a low-risk test that provides useful information. However, don’t start taking vitamin D supplements without discussing it with your oncologist, as the connection between vitamin D and side effects isn’t yet proven. This research is hypothesis-generating, meaning it suggests an idea worth testing rather than providing definitive guidance. Confidence level: Low to Moderate. More research is needed before vitamin D testing becomes standard practice for predicting side effects.

Cancer patients receiving PD-1/PD-L1 inhibitor therapy should be aware of this research, particularly those with lung cancer since that was the predominant cancer type in this study. Oncologists and immunotherapy specialists should consider this as an emerging area worth monitoring. Patients with known vitamin D deficiency who are about to start immunotherapy may want to discuss vitamin D status with their doctor. This research is less relevant for people not receiving immunotherapy or those with other cancer types, though the principles may eventually apply more broadly.

This is early-stage research, so don’t expect immediate changes to treatment protocols. Larger prospective studies would likely take 2 to 5 years to complete and publish. If vitamin D supplementation does help reduce side effects, benefits wouldn’t be immediate but would likely emerge over weeks to months of treatment. Any changes to standard practice would come after multiple studies confirm the findings and doctors develop clear guidelines.

Frequently Asked Questions

Does low vitamin D cause side effects from cancer immunotherapy?

The connection isn’t yet proven. A 2026 study of 35 patients found low vitamin D associated with more side effects, but researchers cannot confirm causality because side effects often occurred before vitamin D was measured. Larger prospective studies are needed to establish whether low vitamin D actually causes these problems.

Should I take vitamin D supplements if I’m getting PD-1/PD-L1 inhibitor treatment?

Discuss this with your oncologist before starting supplements. While this research suggests vitamin D may be relevant, it’s not yet strong enough to recommend routine supplementation. Your doctor can check your vitamin D level and advise based on your individual situation and overall treatment plan.

What vitamin D level is considered deficient for cancer patients?

This study classified deficient as below 30 nmol/L, insufficient as 30 to below 50 nmol/L, and sufficient as 50 nmol/L or higher. However, optimal vitamin D levels may vary by individual and medical condition. Ask your doctor what target range is appropriate for you.

Can checking my vitamin D level predict if I’ll have side effects from immunotherapy?

Not yet. While this study found an association, researchers emphasize the findings cannot predict individual risk. Many factors influence side effects, and vitamin D is just one potential piece. Your doctor considers your overall health, cancer type, and other factors when predicting treatment tolerance.

These are unwanted side effects caused by the immune system becoming overactive during treatment. They can affect various organs including the lungs, skin, digestive system, and hormonal glands. Severity ranges from mild to serious, and doctors grade them using standardized scales to guide treatment decisions.

Want to Apply This Research?

  • Track your vitamin D levels before starting immunotherapy and at regular intervals during treatment (every 4 to 8 weeks). Record the specific measurement in nmol/L or ng/mL, note any immune-related side effects that occur, and log the dates. This creates a personal record you can share with your oncology team.
  • Work with your doctor to establish a baseline vitamin D level before starting PD-1/PD-L1 inhibitor therapy. If your level is low or insufficient, discuss whether supplementation is appropriate for your situation. Use the app to set reminders for vitamin D testing appointments and to log any side effects you experience, helping your medical team identify patterns.
  • Create a timeline view in the app showing your vitamin D measurements alongside any immune-related side effects you experience. This visual comparison helps you and your doctor see if there’s a relationship in your individual case. Set monthly check-in reminders to review your vitamin D status and side effect patterns with your oncology team, ensuring this information informs your ongoing treatment decisions.

This research is exploratory and hypothesis-generating; it cannot establish that low vitamin D causes side effects from immunotherapy or predict individual risk. The study is small (35 patients) and retrospective, with timing uncertainties that limit conclusions. Do not start, stop, or change vitamin D supplementation based on this research without consulting your oncologist. If you’re receiving PD-1/PD-L1 inhibitor therapy and experience any side effects, contact your medical team immediately. This article is for educational purposes and should not replace professional medical advice from your healthcare provider.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Association Between Serum 25-Hydroxyvitamin D Levels and Immune-Related Adverse Events During PD-1/PD-L1 Inhibitor Therapy: A Retrospective Study. , Drug design, development and therapy (2026). PubMed 42928853 | DOI
Topics
vitamin D immunotherapy PD-1 PD-L1 inhibitors side effects immune-related adverse events cancer immunotherapy complications vitamin D deficiency cancer immunotherapy safety monitoring lung cancer treatment 25-hydroxyvitamin D levels